[1]CurrentPatentAssignee:NERVIANOMEDICALSCIENCESS.R.L.-WO2008/74788,2008,A1Locationinpatent:Page/Pagecolumn103-104
[1]CurrentPatentAssignee:NERVIANOMEDICALSCIENCESS.R.L.-WO2008/74788,2008,A1Locationinpatent:Page/Pagecolumn96
[1]CurrentPatentAssignee:NERVIANOMEDICALSCIENCESS.R.L.-WO2011/12534,2011,A1Locationinpatent:Page/Pagecolumn12
[1]CurrentPatentAssignee:NERVIANOMEDICALSCIENCESS.R.L.-WO2011/12534,2011,A1Locationinpatent:Page/Pagecolumn12
[1]Beria,Italo;Bossi,RobertoT.;Brasca,MariaGabriella;Caruso,Michele;Ceccarelli,Walter;Fachin,Gabriele;Fasolini,Marina;Forte,Barbara;Fiorentini,Francesco;Pesenti,Enrico;Pezzetta,Daniele;Posteri,Helena;Scolaro,Alessandra;Depaolini,StefaniaRe;Valsasina,Barbara[BioorganicandMedicinalChemistryLetters,2011,vol.21,#10,p.2969-2974]
Title: NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
Journal: Molecular cancer therapeutics 20120401
Title: NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
Journal: Bioorganic & medicinal chemistry letters 20110515
Title: Beria I, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo,3-hquinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74.
Title: Valsasina B, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr;11(4):1006-16.
Title: Casolaro A, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8(3):e58424.
